Clinical Trial Update: Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

Phase 3 trial update on the safety of HBM9161 (HL161) given subcutaneously in generalized myasthenia gravis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• HBM9161 (HL161) (HBM9161)

Snippet

Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. | Conditions: Myasthenia Gravis | Phase 3 | Status: UNKNOWN